nach oben

International Journal of Hematology

Erschienen in:

01.03.2010 | Rapid Communication

mRNA expression of the XAGE-1 gene in human acute leukemia

verfasst von: Yuqiang Ji, Wanggang Zhang, Jin Wang, Liufang Gu

Erschienen in: International Journal of Hematology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

XAGE-1 is a cancer-testis antigen, which was demonstrated to be expressed at a significant frequency and to be immunogenic in some solid tumors. We analyzed the expression of 4 XAGE-1 transcript variant gene in human acute leukemias by reverse-transcription polymerase chain reaction. Among the 114 acute leukemias, 14/63 (22.22%) of the acute myeloid leukemia samples were positive for XAGE-1b genes. XAGE-1b mRNA expression was detected in 10/51 (19.61%) of the acute lymphocyte leukemia samples. However, we did not find any important correlation between XAGE-1b mRNA expression and clinical characteristics, such as sex, leukemia type, response to therapy and the percentage of blast in the first diagnosed bone marrow. We concluded that the XAGE-1b gene was expressed at the mRNA level in a proportion of human acute leukemia.

Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5:615–25.CrossRefPubMed

Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002;188:22–32.CrossRefPubMed

Sahin U, Türeci O, Chen YT, Seitz G, Villena-Heinsen C, Old LJ, et al. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int J Cancer. 1998;78:387–9.CrossRefPubMed

Tajima K, Obata Y, Tamaki H, Yoshida M, Chen YT, Scanlan MJ, et al. Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer. 2003;42:23–33.CrossRefPubMed

Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer. 2001;85:713–20.CrossRefPubMed

Atanackovic D, Blum I, Cao Y, Wenzel S, Bartels K, Faltz C, et al. Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. Cancer Biol Ther. 2006;5:1218–25.PubMed

Bender A, Karbach J, Neumann A, Jäger D, Al-Batran SE, Atmaca A, et al. LUD 00–009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun. 2007;19:7–16.

Diefenbach CS, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res. 2008;14:2740–8.CrossRefPubMed

Greiner J, Schmitt M. Cancer testis/germline antigens (CT/CG-antigens) in leukemias. Leuk Res. 2007;31:1–3.CrossRefPubMed

10.

Meklat F, Li Z, Wang Z, Zhang Y, Zhang J, Jewell A, et al. Cancer-testis antigens in haematological malignancies. Br J Haematol. 2007;136:769–76.CrossRefPubMed

11.

Lim SH, Austin S, Owen-Jones E, Robinson L. Expression of testicular genes in haematological malignancies. Br J Cancer. 1999;81:1162–4.CrossRefPubMed

12.

Brinkmann U, Vasmatzis G, Lee B, Pastan I. Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res. 1999;59:1445–8.PubMed

13.

Zendman AJ, Van Kraats AA, Weidle UH, Ruiter DJ, Van Muijen GN. The XAGE family of cancer/testis-associated genes: alignment and expression profile in normal tissues, melanoma lesions and Ewing’s sarcoma. Int J Cancer. 2002;99:361–9.CrossRefPubMed

14.

Koizumi F, Noguchi Y, Saika T, Nakagawa K, Sato S, Eldib AM, et al. XAGE-1 mRNA expression in prostate cancer and antibody response in patients. Microbiol Immunol. 2005;49:471–6.PubMed

15.

Nakagawa K, Noguchi Y, Uenaka A, Sato S, Okumura H, Tanaka M, et al. XAGE-1 expression in non-small cell lung cancer and antibody response in patients. Clin Cancer Res. 2005;11:5496–503.CrossRefPubMed

16.

Kikuchi E, Yamazaki K, Nakayama E, Sato S, Uenaka A, Yamada N, et al. Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens. Cancer Immun. 2008;28:8–13.

17.

Egland KA, Kumar V, Duray P, Pastan I. Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Mol Cancer Ther. 2002;1:441–50.PubMed

18.

Morishita Y, Uenaka A, Kaya S, Sato S, Aji T, Nakayama E. HLA-DRB1*0410-restricted recognition of XAGE-1b37–48 peptide by CD4 T cells. Microbiol Immunol. 2007;51:755–62.PubMed

19.

Shimono M, Uenaka A, Noguchi Y, Sato S, Okumura H, Nakagawa K, et al. Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T cells. Int J Oncol. 2007;30:835–40.PubMed

Titel: mRNA expression of the XAGE-1 gene in human acute leukemia
verfasst von: Yuqiang Ji
Wanggang Zhang
Jin Wang
Liufang Gu
Publikationsdatum: 01.03.2010
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 2/2010
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-010-0527-7

Springer Medizin

mRNA expression of the XAGE-1 gene in human acute leukemia

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

A case of congenital bone marrow failure with radio-ulnar synostosis

Incidence of koilonychia and atrophy of the lingual papillae in a patient with iron-deficiency anemia

Non-cirrhotic extrahepatic portal vein thrombosis: a 6-year long case history

Reply to the letter by Bedognetti et al. “Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era”

Development of Kaposi’s sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient

The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie